News about "investigational therapy"

Jazz Pharmaceuticals to Acquire Actio Biosciences for USD 1.32 Billion to Advance Rare Epilepsy Therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for USD 820 million upfront and up to USD 500 million in contingent payments, expanding its rare epilepsy pipeline with investigational therapy ABS-1230.

Investigational Therapy | 12/08/2026 | By News Bureau

Sobi and Innate Pharma Partner to Advance Lacutamab in T-Cell Lymphoma

Sobi and Innate Pharma partners to advance lacutamab into the TELLOMAK-3 Phase 3 trial, supporting its potential accelerated approval in Sézary syndrome and future development across cutaneous T-cell lymphoma.

Investigational Therapy | 10/08/2026 | By News Bureau

Marvel Biosciences Reports Positive Preclinical Results for MB-204 in Fragile X Syndrome Study

Marvel Biosciences has reported positive preclinical results for its lead drug candidate, MB-204, in a Fragile X syndrome study conducted with the FRAXA Research Foundation. The findings further support the therapy's potential to treat autism spectrum disorder and related neurodevelopmental conditions.

Investigational Therapy | 06/08/2026 | By News Bureau

Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL

Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.

Investigational Therapy | 28/07/2026 | By News Bureau

OKYO Pharma Receives FDA Support to Advance Urcosimod into Global Phase 3 Trial

Positive feedback from the US FDA has reinforced OKYO Pharma's clinical development strategy for urcosimod, with the company preparing to launch a global Phase 3 trial for neuropathic corneal pain, a debilitating eye disorder that currently lacks FDA-approved therapies.

Investigational Therapy | 13/07/2026 | By News Bureau |  113

INTENT Biologics Secures FDA Breakthrough Therapy Tag for Diabetic Foot Ulcer Treatment Candidate

INTENT Biologics' PEP Biologic receives FDA Breakthrough Therapy designation for diabetic foot ulcers, accelerating development of its first-in-class exosome-based regenerative treatment aimed at improving healing outcomes in chronic wounds.

Investigational Therapy | 03/07/2026 | By News Bureau |  230

Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD

Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.

Investigational Therapy | 01/07/2026 | By News Bureau

GCAR and Purdue Pharma Launch Tinostamustine in GBM AGILE Trial

GCAR and Purdue Pharma LP initiate Tinostamustine enrolment in the GBM AGILE Phase 2/3 trial, advancing potential new treatment options for glioblastoma patients.

Investigational Therapy | 09/04/2026 | By News Bureau |  131

Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity

Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.

Investigational Therapy | 21/03/2026 | By News Bureau |  352

GentiBio Doses First Patient in Phase I Trial of Novel Cell Therapy for Type 1 Diabetes

GentiBio initiates Phase I POLARIS trial of GNTI-122, an engineered Treg therapy aimed at preserving insulin production and reducing lifelong insulin dependence in newly diagnosed type 1 diabetes patients.

Investigational Therapy | 19/03/2026 | By News Bureau |  212